Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug Combination Opens Clogged Arteries Faster, Keeps Them Open Longer

21.11.2002


By taking continuous electrocardiogram (ECG) readings for 24 hours after treating heart attack patients, Duke University Medical Center researches have shown that giving a combination of a new drug that prevents platelets from clumping together, as well as a clot-busting drug, opens up clogged arteries faster and keeps them open longer.



The researchers found that giving the anti-clotting drug eptifibatide along with a half-dose tenecteplase (TNK) -- a genetically altered version of the commonly used clot-busting agent t-PA -- improved the speed and endurance of restored blood flow to the heart. Eptifibatide is one of a new class of drugs used to prevent the aggregation of platelets in the bloodstream, a process that can lead to the formation of new blood clots, causing potentially dangerous complications.

Duke cardiologists Matthew Roe, M.D., and Mitchell Krucoff, M.D., conducted an additional analysis on a subset of patients enrolled in a larger clinical trial comparing the dual-drug strategy with a TNK-only treatment. His analysis was unique in that he used a portable heart monitoring device which continuously recorded the heart?s electrical activity for 24 hours.


"By taking these continuous readings of the heart’s response to these drugs, we were able see very precisely in time how these drugs acted," said Roe, who presented the results of the Duke analysis today (Nov. 20, 2002) at the 75th annual scientific session of the American Heart Association.

Specifically, Roe found that patients given the combination therapy saw their ECG readings return to stable levels within 55 minutes, compared to 98 minutes for the full-dose, TNK-only group. Additionally, 89.4 percent of the combination therapy patients had returned to stable ECG status by two hours, compared to 67.7 percent for the other group.

"Just as importantly, only 34 percent of the patients who received both drugs suffered from recurrent ischemia (impaired blood flow), compared to 57 percent for the group that didn’t receive eptifibatide," Roe said. "This analysis shows that the combination therapy not only appears to help open clogged vessels faster, but keeps them open longer."

Roe studied a smaller group of patients enrolled in the larger Phase II INTEGRITI trial, which compared two treatments strategies for patients arriving at the hospital with a heart attack -- full-dose TNK vs. half-dose TNK plus eptibfibatide. In his smaller sub-study, Roe performed 24-hour ECG monitoring on 45 patients receiving full-dose TNK and 73 patients receiving the combination therapy.

With an ECG monitor, cardiologists can measure the electrical activity of the hearth with each beat. The monitor turns this electrical activity into a graphic representation of the heart’s beating action, with characteristic patterns or "waveforms" revealing important information about the state of the heart.

In a typical portable ECG test called a "Holter" monitor, two to three leads or ECG waveforms are continuously recorded from each patient. In the current study, researchers took continuous measurements over 24 hours using a portable ECG monitor with 12 leads, which provided much more detailed information about the heart. This approach was developed by Krucoff.

The electrical information received by the ECG monitor is transformed into "mountain-and-valley" graphic plots that display the ECG behavior over time. According to Roe, the higher the mountain peaks, the more the heart is being deprived of oxygen-rich blood, indicating blockages. To get an idea of how the heart is responding, the researchers calculate the area under the mountain. As vessels open up and the heart receives blood, the mountains get smaller and the area under them decreases.

"When conventional ECGs are taken, they run for about 30 seconds, which gives you a snapshot of the heart’s activity, but not the total picture," Roe said. "By collecting data for a much longer period, we obviously gather much greater volumes of detailed data. Instead of a snapshot, it’s more like a movie."

With this approach, the researchers were able to follow how the drugs worked over time. For example, the researchers determined that the area had decreased by half within 30 minutes in 57.7 percent of the patients treated with the combination, compared to 43.8 percent in the single drug group. At 60 minutes, 82.7 percent vs. 65.6 percent had achieved this milestone, and by 90 minutes, 90.4 percent vs. 78.1 percent had shown this improvement.

"While these studies show a beneficial effect of this combination therapy, we need to analyze the results of larger randomized trials to better understand if this early reperfusion has any effect on outcome," Roe said.

A Phase II I trial dubbed ADVANCE-MI, being led by Duke cardiologists, is currently under way to answer these questions.

The INTEGRITI trial was funded by Millennium Pharmaceuticals, Cambridge, Mass., and Schering-Plough, Kennilworth, N.J. Roe is on the speaker?s bureau for both companies, but has no financial interest in either company.

Additional Duke members of the team were Cindy Green, Ph.D., Suzanne Crater, Karen Hannan, and Robert Harrington, M.D, as well as Robert Giugliano, from Brigham and Womens Hospital, Boston.

Richard Merritt | EurekAlert!
Further information:
http://dukemednews.org/news/article.php?id=6077

More articles from Health and Medicine:

nachricht A 'half-hearted' solution to one-sided heart failure
24.11.2017 | Boston Children's Hospital

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

IceCube experiment finds Earth can block high-energy particles from nuclear reactions

24.11.2017 | Physics and Astronomy

A 'half-hearted' solution to one-sided heart failure

24.11.2017 | Health and Medicine

Heidelberg Researchers Study Unique Underwater Stalactites

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>